The lipid lowering effect of plant sterol ester capsules in hypercholesterolemic subjects by Acuff, Robert V et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Lipids in Health and Disease
Open Access Research
The lipid lowering effect of plant sterol ester capsules in 
hypercholesterolemic subjects
Robert V Acuff1, David J Cai*2, Zhi-Ping Dong1 and Doris Bell3
Address: 1East Tennessee State University, College of Medicine, Johnson City, TN, USA, 2Cognis Corporation, LaGrange, IL, USA and 3Cognis 
Deutschland GmbH & Co. KG, Monheim, Germany
Email: Robert V Acuff - acuffr@etsu.edu; David J Cai* - david.cai@cognis.com; Zhi-Ping Dong - dong@etsu.edu; 
Doris Bell - doris.bell@cognis.com
* Corresponding author    
Abstract
Background: Foods enriched with phytosterols have been proven to be an effective therapy to
improve blood lipid profiles. However, none of the studies have investigated the efficacy in lipid
lowering of plant sterol esters (PSE) in capsule form. The objective of this study is to determine if
the plant sterol esters (PSE) in capsule form (1.3 grams of PSE/day) lowered plasma cholesterol
levels and lipid ratios in free-living hypercholesterolemic subjects during a 4-week intervention
period.
Methods: Sixteen subjects participated in a double-blind, placebo-controlled, sequential study
with a 4-week placebo phase followed by a 2-week wash-out period and a 4-week treatment phase.
Subjects were instructed to maintain stable diet pattern and physical activities. Blood samples were
collected at 7, 21 and 28 days of each phase. The primary measurements were change in plasma
total cholesterol (TC), HDL-cholesterol (HDL) and LDL-cholesterol (LDL) between phases and
within each phase. The secondary measurements were change in triglycerides, lipoprotein ratios
(TC/HDL, LDL/HDL) and C-reactive protein (CRP).
Results: In comparison to placebo, LDL-cholesterol was significantly reduced by 7% and 4% (P <
0.05) at both week 3 and week 4; HDL at week 3 of the treatment was significantly increased by
9% (P < 0.01), but not at week 4 (4%); total cholesterol was not significantly different from placebo
throughout the period, TC/HDL and LDL/HDL were significantly reduced by (8%, 8%, 6%, 10%,
respectively) (P < 0.01) at both week 3 and week 4. CRP and triglycerides did not differ either
between the two phases or during the treatment phase.
Conclusion: In conclusion, plant sterol ester capsule is effective in improving lipid profiles among
hypercholesterolemic subjects in a free-living setting at the minimum dosage recommended by
FDA. The significant improved lipid profiles were reached after three weeks of administration. To
achieve better lipid lowering results, higher dosages and combination with diets low in saturated
fat and cholesterol are recommended.
Background
Elevated LDL-cholesterol is a significant risk factor for cor-
onary artery disease. The use of statin drugs is the current
therapeutic option for lowering LDL-cholesterol and
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improving lipid profile in hypercholesteremic patients.
According to the American Heart Association guidelines,
other options should be considered as well to treat or pre-
vent hypercholesterolemia, including the use of phyto-
sterols. Phytosterols, either as plant sterols or plant
stanols, are natural cholesterol-like substances derived
from plants [1]. The main mechanism by which phyto-
sterols reduce blood cholesterol is to inhibit cholesterol
absorption in the small intestine. Therefore, the physical
forms, carriers and solubilization of the phytosterols are
important characteristics to determine the efficacy of phy-
tosterols on cholesterol lowering [2].
In terms of physical forms, free phytosterols are water and
oil insoluble. The efficacy on lowering blood cholesterol
of free phytosterols is often dependant on the dispersion
capability in water and oil [3-5]. Recently, soy lecithin has
been used to form more dispersible complexes with free
sterol or stanol resulting in more bioavailable free sterol/
stanol formulation than previous formulations [6-8].
However, the improved efficacy has only been confirmed
in tablet forms, but not in the capsule form [7,8]. Fatty
acid esters of sterols or stanols, on the other hand, are oil
soluble. Thus, they are more easily dispersible in oils than
free sterols or stanols which make them a better choice for
soft gel capsules than the free sterol/stanol.
In terms of carriers, there is abundant evidence suggesting
LDL-cholesterol lowering efficacy of phytosterols either as
plant sterols or stanols in food forms, including water
emulsions [3]; water as lecithin micelles [9]; yogurt
[10,11]; low fat milk [12,13]; chocolate [14]; cereal; snack
bars, breads, and beverages [15,16]. However, there are
very few studies that investigated if these compounds pro-
vided as pharmaceutical forms, such as tablets and cap-
sules, offer the same benefits [2,7,8]. The information on
non-food forms is essential for long term supplementa-
tion strategy. As indicated by Law et al, (1994 and 2003),
to achieve life saving benefits from mortality associated
with heart disease and stroke, the LDL-cholesterol lower-
ing strategy needs to be maintained for at least two years,
and preferably for five years [17,18]. The pharmaceutical
dosage forms, such as tablets and capsules, can provide
more convenience and flexibility needed for the recom-
mended long term usage than the traditional food appli-
cations [2]. Furthermore, these forms could be better
delivery vehicles for phytosterols to be incorporated into
the combination therapeutic strategy with pharmaceutical
agents to provide an additional LDL-cholesterol lowering
effect [19-21]. Unfortunately, none of the studies with
these pharmaceutical forms used plant sterol esters [2,8].
Considering plant sterol ester is a more dispersible form
in oil than free phytosterols, phytosterol esters may be
more suitable choice for soft gel capsules than free plant
sterols/stanols.
The present study was designed to confirm the efficacy of
the plant sterol esters (PSE) in capsule form on lipid pro-
file lowering in free-living hypercholesterolemic subjects
during a short term (4 weeks). The dosage used in the
study, 1.3 g plant sterol ester (0.8 g free sterol equivalent),
is the minimum dosage that is recommended by FDA's
health claim [22]. The information will be essential for
usage of plant sterol esters in supplement forms beyond
current food applications.
Results
No subject was dismissed because of the inability to toler-
ate the treatment or placebo or because of an adverse
action or event. The statistical evaluation was determined
based upon the 16 remaining subjects who completed the
total study.
Placebo vs. treatment
Total cholesterol was reduced, but not significantly, at the
end of treatment period (5%) (P = 0.07) (Table 1, Figure
1). LDL-cholesterol, TC/HDL, LDL/HDL ratios were sig-
nificantly reduced by 7% (P < 0.05), 8% (P < 0.01) and
6% (P < 0.01) at day 21, 4% (P < 0.05), 8% (P < 0.01) and
10% (P < 0.01) at day 28, respectively (Table 1, Figure 1).
HDL at day 21 of the treatment was significantly higher in
comparison to placebo (9%, P < 0.01), but not at day 28
(4%) (Table 1, Figure 2). CRP and triglycerides did not
differ between placebo and treatment phase.
Within each phase
There was no significant change in any of the measure-
ments within the placebo phase (Table 1). Within the
treatment phase, in comparison to day 7, LDL was signif-
icantly reduced at day 21(P < 0.05), but not at day 28
(Table 1, Figure 1); HDL was significantly increased at
both day 21 and 28 (P < 0.05) (Table 1, Figure 2); TC/
HDL and LDL/HDL ratios were significantly reduced at
both day 21 and 28 (P < 0.001) (Table 1). Total choles-
terol was reduced throughout the treatment phase, but
this reduction was not significant. CRP and triglycerides
did not change during the treatment phase.
Discussion
The cholesterol lowering effect of plant sterols, either as
free or esterified forms, is well documented in the litera-
ture. Most studies used food forms as delivery vehicles.
There are only a few studies that have evaluated the effec-
tiveness of phytosterols in tablet or capsule form, all of
which used free stanols [7,8,23]. To our knowledge, the
present study is the first study to demonstrate a significant
reduction in plasma LDL cholesterol by 4% with plant
sterol esters in capsules (P < 0.05). Epidemiological stud-
ies have shown that such a 4–5% reduction of LDL corre-
lates with a 5–10% reduction in CHD risk in the first 5
years, and by 10% over a life time [24]. This result indi-Lipids in Health and Disease 2007, 6:11 http://www.lipidworld.com/content/6/1/11
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cates that regular use of plant sterol esters in a soft gel cap-
sule could contribute significant benefits to long term
cholesterol management as the food delivery forms. Pre-
vious studies with phytosterol fortified foods have shown
reductions of 5% or more in LDL cholesterol levels rela-
tive to a control. For example, in men and women with a
wide range of age and baseline cholesterol levels, 0.8 g of
free sterol equivalents administrated as sterol ester in
spreads decreased LDL cholesterol by 6% [25], and 1.1 g/
d of free sterol equivalents in spreads as plant sterol ester
decreased LDL-cholesterol by 4.9% [26]. The significant
4% reduction in plasma LDL-C in the present study indi-
cates that regular use of plant sterol esters is equally effec-
tive in a soft gel capsule form compared to food delivery
forms of similar doses.
This study was conducted in free-living subjects without
collection of dietary records at baseline or during the
study. Subjects were advised to maintain regular dietary
habits and physical activity. This practical approach was
meant to mimic plant sterol capsules consumption under
various background diets. Previously, plant sterols were
said to be more effective when consumed with diets con-
taining higher levels of cholesterol or fat [2,27], more
recent studies indicated that since plant sterols impair
both dietary and bilary cholesterol absorption, they are
effective even when consumed with low fat diets [28-30].
Thus, the delivery regimen for the plant sterols is more
crucial than the background diet. In the present study, all
subjects were advised to take the capsules with each meal
(lunch and dinner). As long as plant sterols are taken with
meals to stimulate the bilary flow, they can effectively
lower cholesterol within the context of various diets and
food forms [2].
The present study showed significantly (p < 0.01)
improved lipid ratios (TC/HDL and LDL/HDL) either
independent of placebo or relative to placebo. These
results are in agreement with previous reported studies
using free stanols [7,8] or sterol esters [31]. The improved
lipid ratios are due to reduced LDL, total cholesterol and
increased HDL levels during the treatment phase. While
most studies published to date have reported that phyto-
sterols have little or no effect on HDL, even with long-
term use [5,32], in our study HDL level was increased dur-
ing the treatment period as compared to placebo (P <
0.05). A recent study using orange juice with plant sterols
also observed an increase in HDL [33], In studies using
plant sterol esters in combination with exercise, signifi-
cant increase in HDL was observed [34,35]. Since this was
a cross-over study and the effect was not observed during
placebo phase, it is likely to be a consequence of plant
Table 1: Effects of plant sterol ester capsules on plasma lipid profiles and CRP (n = 16)1
Parameters Initial Baseline 2 Day 7 Day 21 Δ PSE-Placebo Day 28 Δ PSE-Placebo
Total Cholesterol (mg/dL) 256.0 ± 24.3
Placebo phase 238.4 ± 18.8 239.3 ± 28.3 241.6 ± 27.2
Treatment phase 239.9 ± 29.6 237.4 ± 29.2 -1.9 (-1%) 230.4 ± 22.3 -11.2 (-5%)
LDL (mg/dL) 177.1 ± 22.8
Placebo phase 168.5 ± 22.9 169.8 ± 25.6 169.4 ± 27.0
Treatment phase 170.8 ± 27.7 157.8 ± 22.8 A, a -12 (-7%) 163.3 ± 27.0A -6.1 (-4%)
HDL (mg/dL) 57.8 ± 19.9
Placebo phase 50.4 ± 13.8 49.1 ± 13.6 51.2 ± 15.4
Treatment phase 50.8 ± 15.5 53.3 ± 16.3A, a 4.2 (9%) 53.5 ± 16.3a 2.3 (4%)
Triglycerides 125.9 ± 81.4
Placebo phase 116.6 ± 60.8 122.7 ± 89.0 126.5 ± 74.6
Treatment phase 111.4 ± 69.8 121.7 ± 71.4 -1 (< -1%) 115.7 ± 63.6 -10.8 (-9%)
Total Cholesterol/HDL 4.89 ± 1.64
Placebo phase 5.1 ± 1.4 5.2 ± 1.6 5.1 ± 1.6
Treatment phase 5.1 ± 1.5 4.8 ± 1.6A, a -0.4 (-8%) 4.7 ± 1.4A, a -0.4 (-8%)
LDL/HDL 3.44 ± 1.28
Placebo phase 3.6 ± 1.3 3.6 ± 1.2 3.7 ± 1.2
Treatment phase 3.7 ± 1.2 3.4 ± 1.2 A, a -0.2 (-6%) 3.3 ± 1.2A, a -0.4 (-10%)
CRP (mg/dL) 0.8 ± 0.5
Placebo phase 0.7 ± 0.4 0.7 ± 0.4 0.7 ± 0.5
Treatment phase 0.8 ± 0.6 0.8 ± 0.5 0.07 (5%) 0.7 ± 0.3 0
1 Values are means ± SD.
2 Initial baseline measurement was done 6 week before the placebo phase. Therefore, the data was not included in any analysis, but are provided as 
reference information
A Significantly different from placebo, p < 0.05 (paired t-test)
a Significantly different within phase, p < 0.05 (1-way repeated measure ANOVA)Lipids in Health and Disease 2007, 6:11 http://www.lipidworld.com/content/6/1/11
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sterol ester. A longer term administration is needed to fur-
ther confirm the positive effect of plant sterol ester on
HDL levels.
Due to the difference in physical and chemical character-
istics between esterized and free forms, plant sterol esters
may be a better choice for capsules than their free form.
Theoretically, both esters and free forms should possess
similar cholesterol lowering effect if the free sterols are
properly solubilized. Improperly dispersed formulations,
such as aqueous or oil-based suspensions of solid sterols,
have been reported as unsuccessful in lowering LDL-cho-
lesterol. These formulations included a crystalline aque-
ous suspension of sitosterol [36], capsules containing 3 g
of stanol powder dispersed in safflower oil [23], or free
sterols in beverages with low fat [6]. In addition to the dis-
persion factor, these studies suggested that the crystal
form of free sterol/stanols may be another important fac-
tor determining their solubility in intestinal fluid and
their effectiveness to inhibit cholesterol absorption [37].
To enhance its solubilization in water or oils, the free
plant sterols or stanols are usually added to other sub-
stances and often require the presence of fat to facilitate
the emulsion. Thus, the method of dispersion, processing,
and use of emulsifiers, surfactants, and crystal habit mod-
ifiers plays a crucial role in delivering small crystals of free
phytosterols over time to sufficiently maintain their bioa-
vailability [2,12,13]. A recent breakthrough in formula-
tion, using soy lecithin to form more water dispersible
and bioavailable complexes with free stanol, has been
demonstrated to lower plasma cholesterol and LDL in two
recent studies in tablet form [7,8]. In a placebo controlled,
The effect of plant sterol ester on LDL – cholesterol (mg/dL) (N = 16) Figure 1
The effect of plant sterol ester on LDL – cholesterol (mg/dL) (N = 16). A Significantly different from placebo, p < 0.05 
(paired t-test) a Significantly different within phase, p < 0.05 (1-way repeated measure ANOVA)
150.00
155.00
160.00
165.00
170.00
175.00
180.00
7 1 42 12 8
Days during each phase
L
D
L
-
C
 
(
m
g
/
d
L
)
Placebo
Treatment
A,a
A
 Lipids in Health and Disease 2007, 6:11 http://www.lipidworld.com/content/6/1/11
Page 5 of 10
(page number not for citation purposes)
double-blind study by McPherson et al. [7], free stanols
were emulsified with soy lecithin and the spray dried
preparation was used to make tablet and capsule forms
that were tested in 26 subjects per group over a 6-week
period. The group that received tablet form experienced
reduction in both LDL cholesterol and LDL/HDL ratio by
10.4% and 11.5% respectively. However, no reduction
was observed in the group that received capsules [7]. The
author attributed the difference in LDL reduction to the
variation in disintegration times, in so far that the tablet
disintegrated much faster than the capsule form (10 min.
vs. 45 min., respectively).
Fatty acid esters of sterols or stanols are oil soluble. Thus,
they are more easily dispersible in oils than free sterols or
stanols. Additionally, plant sterol esters are well distrib-
uted in the small intestine providing ample surface area
for incorporation into bile salt micelles through the diges-
tive process in order to inhibit cholesterol absorption
[2,24]. Earlier evidence suggested that even though the
cholesterol lowering effect is similar between free sterols
and stanols, the saturation state of their esterified forms
may affect the ability to reduce cholesterol absorption
[38]. In a clinical study conducted by Jones et al. (2000),
intake of plant sterol esters from margarine resulted in
larger LDL reductions than margarine with stanol ester
(13% vs. 8%, respectively) [38]. However, taking the
totality of evidence into account, sterol and stanol esters
are probably equal in their cholesterol-lowering effect.
Nevertheless, plant sterol esters remain a better choice for
soft gel capsules despite the improvements in free sterols
formulation to increase the bioavailability.
The effect of plant sterol ester on HDL – cholesterol (mg/dL) (N = 16) Figure 2
The effect of plant sterol ester on HDL – cholesterol (mg/dL) (N = 16). A Significantly different from placebo, p < 0.05 
(paired t-test) a Significantly different within phase, p < 0.05 (1-way repeated measure ANOVA)
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Finally, this study evaluated the effect of PSE on CRP, a
proposed risk factor in cardiovascular disease [39]. All
subjects in this study had low or average CRP levels (<3.0
mg/L) at baseline and PSE had no effect on CRP during
the treatment phase. It has been demonstrated that diet
can have a beneficial impact on CRP levels as observed in
the "portfolio diet", a dietary prescription comprised of
several foods and food components (including plant
sterol esters) which are known to reduce cholesterol levels
[40]. In the present study, due to the free-living study
design, it is unlikely that CRP will be changed solely based
on plant sterol ester treatment.
There are several limitations of this study. First, the study
treatments were not randomized. The placebo and PSE
treatment were conducted sequentially with wash-out
period in between. There is some evidence suggesting a
carry-over effect from phytosterol treatment to the pla-
cebo group [41] in randomized crossover design. The
sequential design could minimize the carry-over effect
since the placebo phase was performed first. To minimize
the potential confounding effect due to the sequential
design, such as time drifting effect, additional within
group comparisons were conducted using repeated meas-
ure analysis. The results from placebo phase did not show
any significant change within the 4-week period whereas
significant changes were found within the treatment
phase. This within group analyses confirmed that the sig-
nificant changes were due to the treatment, not the time
drifting effect.
Another limitation is the lack of true baseline measure-
ments at the beginning of placebo and treatment phase.
This was not intended for the original study design, but
occurred during the study. To compensate for this limiting
factor, the within group analyses were performed to com-
pare measurements at day 21 and 28 to day 7 of each
phase. The significant differences were only detected dur-
ing the treatment phase, not the placebo phase. Addition-
ally, there was no significant difference at day 7 of each
phase between the placebo and treatment suggesting a sig-
nificant treatment effect.
The number of subjects was calculated based on 10%
reduction of total cholesterol. However, given the fact that
the tested dose was 1.3 g plant sterol esters/day as 0.8 g
free sterol equivalent/day, it is arguable that the above
reduction is overestimated. Thus, the study may be under-
powered which could explain the lack of significance in
reduction of total cholesterol (-5%) (P = 0.07). More sub-
jects are needed for further studies with the above dosage.
Nevertheless, the present study showed a significant
improvement in LDL-C occurred with the present number
of subjects indicating that the effect of plant sterol ester is
significant.
Conclusion
This study is the first study that confirmed regular use of
plant sterol ester capsules is an effective strategy in
improving lipid profiles, especially lipoprotein ratios,
among hypercholesterolemic subjects in a free-living set-
ting without dietary intervention. The clinical advantage
of the capsule form is that it provides a convenient vehicle
to consume without the dietary impact on calories. It can
also easily be incorporated into a cholesterol-lowering
regimen in standard clinical practice with counseling or
therapeutic lifestyle changes including those recom-
mended by the National Cholesterol Education Program
[24,42]. The significant improvement in LDL-C occurred
in free-living subjects with little dietary control indicates
that the effect of plant sterol ester is fairly significant
regardless of the delivery vehicle and background diet.
However, to achieve better lipid lowering effects, higher
dosages and incorporation of cholesterol-lowering regi-
men are recommended. Further studies are needed to con-
firm the long term benefit of plant sterol ester capsules on
blood cholesterol in populations with varying baseline
cholesterol levels.
Methods
Subjects
The research protocol and informed consent were
approved by the East Tennessee State University (ETSU)
Institutional Review Board (IRB) Committee on Protec-
tion of Human Subjects.
Subject recruitment was conducted by campus advertise-
ment. The questionnaire evaluation and hematological
screening of potential subjects were conducted at the
Nutrition Center in the Department of Internal Medicine.
Inclusion criteria included men and women (not preg-
nant or breast feeding), borderline high or elevated serum
lipid parameters, body mass index (BMI) < 30, ability to
maintain stable diet and physical activity, and in other-
wise healthy condition. Candidates were excluded from
the study if they had
￿ diseases or conditions requiring drug intervention;
￿ been taking cholesterol lowering drugs, supplements or
other practices, such as taking cloves of garlic every day
￿ uncontrolled elevated blood pressure (systolic >160
mmHg or diastolic > 95 mmHg)
￿ history or presence of drug or alcohol abuse, or alcohol
intake >7 alcoholic beverages per week within the past 4
weeks
Power calculations based on expected 10% changes in
total cholesterol levels determined that at least 16 subjectsLipids in Health and Disease 2007, 6:11 http://www.lipidworld.com/content/6/1/11
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would be needed. Twenty subjects (total cholesterol 227–
308 mg/dL, LDL 129–211 mg/dL and triglycerides 43–
355 mg/dL) were included in the study. During the study
phases, four subjects later withdrew due to either personal
reasons or unable following restrictions, such as not tak-
ing cholesterol lowering supplements. The remaining six-
teen subjects (12 female/4 male, age: 51 ± 13) (total
cholesterol: 256 ± 24 mg/dL; LDL: 177 ± 23 mg/dL) com-
pleted the study. Table 2 presents the baseline means for
the parameters of interest, including age and lipid values,
for the 16 subjects who completed the study. Only data
from the sixteen subjects were included for analysis.
Materials
Both placebo (containing soybean oil) and matching
plant sterol ester capsules were manufactured by Cardinal
Health (Dublin, OH). The plant sterol esters (Vegapure®
95) were manufactured by Cognis Corporation
(LaGrange, IL). The plant sterol esters were prepared by
esterification of free plant sterols from a mixture of soy,
rapeseed and other vegetable sources, with fatty acids
from sunflower oil. Mixed tocopherols and ascorbyl
palmitate are used in the formulation as antioxidants and
chemical preservatives. Soybean oil is used as a coating
agent and texturizer (see Table 3, Table 4).
Study design and intervention phases
The study was a double-blind, placebo-controlled, non-
randomized, sequential study. After the initial baseline
measurements which were conducted in late December,
there was a six-week period before the placebo phase to
minimize lipid profile variance. For this reason, the initial
baseline data was not used for comparison to any data col-
lected in placebo and treatment phases
Six weeks after the initial baseline measurement, all sub-
jects were assigned to a placebo phase (soybean oil) for
four weeks followed by a two-week, wash-out period
before proceeding to a four-week treatment phase. Sub-
jects were instructed to take 1 capsule at each of 2 meals
per day (lunch and dinner) during each phase. The PSE
treatment provided a total of 1.3 grams per day of sterol
esters (0.8 grams free plant sterol equivalents). This
amount is the minimum dose recommended in FDA's
health claim for phytosterols [22].
At the beginning of each phase, each subject was given a
bottle containing 60 capsules (56 capsules are needed for
4 weeks and 4 capsules are extra). Placebo capsules and
plant sterol ester capsules were identical in terms of
appearance and sensory characteristics. Compliance was
monitored by counting extra capsules in the bottles at the
end of each phase and questioning subjects regarding
missed doses. Subjects were instructed to maintain their
stable diet pattern and physical activity level during the
study periods. Although general advice on healthy life
style was given to subjects occasionally during their visit
to the Nutrition Center, neither dietary advice was given,
nor were food records collected.
Fasted blood samples were collected at 7, 21 and 28 days
of each phase. The primary measurements were change of
plasma total cholesterol (TC), HDL-cholesterol and LDL-
cholesterol between placebo and treatment. The second-
ary measurements were changes of triglycerides, lipopro-
tein ratios (TC/HDL, LDL/HDL) and CRP.
Lipids and C-Reactive Protein (CRP) analyses
Fasted serum samples were analyzed for triglycerides
(TG), total cholesterol (TC), high density lipoprotein cho-
lesterol (HDL-C), low density lipoprotein cholesterol
(LDL-C), and c-reactive protein (CRP). Total cholesterol,
HDL, triglycerides and CRP were performed at Johnson
City Medical Center Hospital (Johnson City, TN) using an
automated clinical chemistry analyzer (Beckman Syn-
chron LX20; Fullerton, CA). LDL-cholesterol was calcu-
lated using the Friedewald formula.
Statistical analysis
Data were analyzed to detect significant differences
between placebo and treatment by ANOVA. Once the sig-
nificant difference was detected, paired student t-tests was
Table 2: Subject Characteristics at Baseline (n = 16)
Variable Mean + SD Range
Age (yrs) 51 ± 13 25–72
Number of Subjects: Female/Male 12/4
Total Cholesterol (mg/dL) 256.0 ± 24.3 227–308
LDL-Cholesterol (mg/dL) 177.1 ± 22.8 129–211
HDL-Cholesterol (mg/dL) 57.8 ± 19.9 36–110
Triglycerides (mg/dL) 125.9 ± 81.4 43–355
Total Cholesterol/HDL 4.89 ± 1.64 2.25–8.11
LDL-Cholesterol/HDL 3.44 ± 1.28 1.17–5.69
C-Reactive Protein (mg/dL) 0.8 ± 0.5 0.5–1.9
* SD = Standard DeviationLipids in Health and Disease 2007, 6:11 http://www.lipidworld.com/content/6/1/11
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performed to compare the measurements at each blood
collection time (7 day, 21 day and 28 day) between pla-
cebo and treatment group. Additional within-group anal-
ysis was performed by 1-way repeated measures analysis
of ANOVA to compare measurements within placebo or
treatment phase in order to make sure that the expected
changes were not caused by time drift during each phase.
Paired student t-tests were performed to compare meas-
urements at each blood collection time.
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